<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392389</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1653-P101</org_study_id>
    <nct_id>NCT03392389</nct_id>
  </id_info>
  <brief_title>Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moderna Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moderna Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a
      combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy
      adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited AEs (local and systemic reactogenicity events)</measure>
    <time_frame>7 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of unsolicited adverse events</measure>
    <time_frame>28 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAE), adverse events of special interest (AESI), and medically-attended AEs</measure>
    <time_frame>one year following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of clinical laboratory adverse events</measure>
    <time_frame>1 month following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies</measure>
    <time_frame>1 month following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination</measure>
    <time_frame>1 month following the last dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline</measure>
    <time_frame>1 month following the last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies</measure>
    <time_frame>6 months and 1 year following the last dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination</measure>
    <time_frame>6 months and 1 year following the last dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline</measure>
    <time_frame>6 months and 1 year following the last dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Human Metapneumovirus and Human Parainfluenza Infection</condition>
  <arm_group>
    <arm_group_label>mRNA-1653</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1653</intervention_name>
    <description>Escalating dose levels</description>
    <arm_group_label>mRNA-1653</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agrees to comply with the study procedures and provides written informed consent

          -  18 to 49 years of age

          -  Body mass index between 18 and 35 kg/m2

          -  In good health based on medical history, physical examination, vital sign measurements
             and laboratory safety tests performed prior to initial study vaccination

          -  Negative urine pregnancy test at the screening visit and the day of each vaccination
             for females of childbearing potential

          -  Female subjects must either be of non-childbearing potential or use acceptable methods
             of contraception from at least 30 days prior to enrollment and through 3 months
             following last vaccination

          -  Willing to comply with the requirements of the protocol (eg, complete Diary Cards,
             return for follow-up visits, be available for safety phone calls)

        Exclusion Criteria:

          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care

          -  A history of malignancy in the last 10 years

          -  If female and of childbearing potential, is pregnant or lactating, has not adhered to
             an adequate contraception method from at least 30 days before study entry, or does not
             plan to do so for at least 3 months after the last vaccination

          -  Abnormal screening safety laboratory test results including liver enzyme tests

          -  Administration of any investigational or non-registered product (drug or vaccine)
             other than the study vaccine within 30 days preceding the first dose of study vaccine
             or has plans for administration during the study period

          -  Prior administration of investigational agent using lipid nanoparticle formulations

          -  A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or
             human immunodeficiency virus types 1 or 2 antibodies

          -  A positive test result for drugs of abuse

          -  Chronic administration of potentially hepatotoxic drugs or have other medical
             conditions that affect the liver (eg, alcohol abuse)

          -  A history of idiopathic urticaria

          -  Plans for administration or has been administered a vaccine within the period from 30
             days before through 30 days after each study vaccination, with the exception of any
             licensed influenza vaccine administered ≥15 days before or after any study vaccination

          -  Any chronic administration of an immunosuppressant or other immune modifying drug

          -  Prior administration of immunoglobulins and/or any blood products within the 3 months
             before the first study vaccine or has plans for administration during the study period

          -  Any known or suspected immune-mediated disease or immunosuppressive condition as
             determined by medical history and/or physical examination

          -  A history of hypersensitivity or serious reactions to previous vaccinations

          -  Any bleeding disorder considered a contraindication to IM injection or blood draw

          -  Any acute illness or fever at screening

          -  Any condition that, in the opinion of the investigator, would pose a health risk to
             the subject if enrolled or could interfere with evaluation of the study drug or
             interpretation of study results

          -  Donation of blood or blood products &gt; 450 mL within 30 days of dosing.

          -  Is an immediate family member or household member of study personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>855-663-6762</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-933-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>512-478-5416</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>817-238-7254</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-1653</keyword>
  <keyword>human metapneumovirus</keyword>
  <keyword>human parainfluenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

